Luveris
ApprovedSmall molecule
Merck & Co.Luveris is one of 26 small molecule programs targeting Hypogonadotropic Hypogonadism. It is currently in Approved.
1
Indications
6
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
30 competitors in Hypogonadotropic Hypogonadism
#DrugCompanyPhaseTrials
1Femara
NovartisApproved
Andriol
AAuxilium
Approved
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Approved
Delatestryl
AAntares Pharma Inc.
Approved
Human Chorionic Gonadotropin
Merck & Co.Phase 3
Recombinant Human Chorionic Gonadotropin
Merck & Co.Approved
Human Menopausal Gonadotropin
EMD SeronoApproved
Hcg
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 3
Androgel
RRepros Therapeutics Inc.
Phase 3
Clomid
EMD SeronoPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ovarian Stimulation3 trials
Women1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Luveris. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company